Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome
暂无分享,去创建一个
R. Aharonov | A. Schäffer | E. Ruppin | I. Meilijson | M. Gilbert | R. Berger | D. Juric | R. Kurzrock | A. Papanicolau‐Sengos | Z. Ronai | S. Lipkowitz | P. Rajagopal | A. Apolo | Gal Dinstag | Efrat Elis | N. Nair | Danh-Tai Hoang | W. Dahut | Kenneth Aldape | T. Beker | S. Sinha | E. Shulman | Doreen S. Ben-Zvi | O. Tirosh | Eden Maimon | Emmanuel Elalouf | Eyal Schiff | F. Karzai | J. S. Lee | Joo Sang Lee | Boris Temkin | Philipp Vitkovsky
[1] F. He,et al. CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response , 2021, Nucleic Acids Res..
[2] F. Markowetz,et al. Multi-omic machine learning predictor of breast cancer therapy response , 2021, Nature.
[3] A. Haslam,et al. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action , 2021, JAMA network open.
[4] P. Wen,et al. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma , 2021, Clinical Cancer Research.
[5] Rajvi Patel,et al. Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study , 2021, Frontiers in Oncology.
[6] D. Berry,et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. , 2021, Cancer cell.
[7] Y. Jeng,et al. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma , 2021, Liver Cancer.
[8] Yixue Li,et al. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. , 2021, Journal of genetics and genomics = Yi chuan xue bao.
[9] E. Ruppin,et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.
[10] L. Esserman,et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk , 2021, NPJ breast cancer.
[11] Joshua M. Dempster,et al. Integrated cross-study datasets of genetic dependencies in cancer , 2020, Nature Communications.
[12] David J. Sims,et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Jinyu Yu,et al. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma , 2020, bioRxiv.
[14] R. Kurzrock,et al. Review of precision cancer medicine: Evolution of the treatment paradigm. , 2020, Cancer treatment reviews.
[15] Ron Edgar,et al. NCBI gene expression and hybridization array data repository , 2020 .
[16] Mary Goldman,et al. Genomic basis for RNA alterations in cancer , 2020, Nature.
[17] D. Cutler. Early Returns From the Era of Precision Medicine. , 2020, JAMA.
[18] L. Siu,et al. Molecular profiling for precision cancer therapies , 2020, Genome medicine.
[19] A. Kesselheim,et al. Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] J. Doroshow,et al. Genomics and the History of Precision Oncology. , 2020, Surgical oncology clinics of North America.
[21] Aviad Tsherniak,et al. Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines , 2019, bioRxiv.
[22] J Jack Lee,et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.
[23] Adam A. Friedman,et al. Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy , 2018, bioRxiv.
[24] J. Sicklick,et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.
[25] R. Rabadán,et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.
[26] Nuno A. Fonseca,et al. ArrayExpress update – from bulk to single-cell expression data , 2018, Nucleic Acids Res..
[27] Trey Ideker,et al. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. , 2018, Journal of molecular biology.
[28] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[29] V. Mazzaferro,et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial , 2018, Gut.
[30] E. Ruppin,et al. Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.
[31] Paul A Clemons,et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors , 2018, Nature Genetics.
[32] Jörg Menche,et al. Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48 , 2018, Nature Communications.
[33] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[34] Z. Szallasi,et al. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[36] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[37] G. Pupo,et al. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors , 2017, Clinical Cancer Research.
[38] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[39] Alan Ashworth,et al. PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.
[40] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[41] J. Lunceford,et al. IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .
[42] Deborah Schrag,et al. Precision Oncology: Who, How, What, When, and When Not? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[43] M. Dolled-Filhart,et al. Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. , 2016, Archives of pathology & laboratory medicine.
[44] D. Generali,et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[46] Ludmila V. Danilova,et al. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma , 2016, Cancer Immunology Research.
[47] Trey Ideker,et al. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. , 2016, Molecular cell.
[48] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[49] J. Carpten,et al. Translating RNA sequencing into clinical diagnostics: opportunities and challenges , 2016, Nature Reviews Genetics.
[50] L. De Cecco,et al. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab , 2016, Clinical Cancer Research.
[51] Arul M Chinnaiyan,et al. Translating cancer genomes and transcriptomes for precision oncology , 2016, CA: a cancer journal for clinicians.
[52] S. Bicciato,et al. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. , 2015, The oncologist.
[53] O. Gevaert,et al. Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial , 2015, British Journal of Cancer.
[54] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[55] Jean Y. Tang,et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. , 2015, Cancer cell.
[56] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[57] R. Foà,et al. Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients , 2014, American journal of hematology.
[58] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[59] Anton Belousov,et al. Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study , 2014, Clinical Cancer Research.
[60] N. Pavlidis,et al. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG) , 2014, BMC Cancer.
[61] Gary Ruvkun,et al. Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling , 2013, Molecular systems biology.
[62] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[63] Yuan Qi,et al. Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial , 2012, BMC Medical Genomics.
[64] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[65] Gary D Bader,et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer , 2012, Proceedings of the National Academy of Sciences.
[66] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[67] H. Ikeuchi,et al. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[68] Bob Löwenberg,et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. , 2007, Blood.
[69] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[70] David C. Atkins,et al. Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.
[71] A. Alavi,et al. Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.
[72] Gavin D. Grant,et al. Common markers of proliferation , 2006, Nature Reviews Cancer.
[73] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[74] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[75] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[76] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[77] M. Roussel,et al. Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis , 2001, Molecular and Cellular Biology.
[78] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[79] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[80] L. Hartwell,et al. Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.
[81] Donald M. Steinwachs,et al. Promises and pitfalls of the , 1997 .